Intradiscal injection is a minimally invasive, outpatient procedure lasting 20–40 minutes under fluoroscopic or ultrasound guidance. Local anaesthetic infiltration and brief sedation are used; general anaesthesia is avoided. Immediate post-procedure discomfort is mild. Bed rest for 24 hours and activity restriction for 2 weeks optimise disc healing and reduce risk of re-injection. Return to work (desk-based) is possible within 3–5 days; physical labour and heavy lifting are deferred for 6–8 weeks. No prolonged hospitalisation or surgical recovery is required; overall downtime is minimal.
Published trials of intradiscal placental MSC injection demonstrate pain reduction (VAS or Oswestry scales) in 50–65% of participants over 6–12 months. Discography MRI findings show improved hydration signals in 30–50% of treated discs, interpreted as proteoglycan restoration, though correlation with pain outcomes is inconsistent. One phase II trial (67 patients) reported sustained pain relief at 24-month follow-up in 55% of injected discs. Exosome intra-discal delivery is emerging with small proof-of-concept studies showing reduced inflammatory biomarkers in disc fluid post-injection. Comparative data versus sham injection remain limited; most positive evidence derives from open-label or non-blinded designs.
Am I a candidate? → · Back & Disc Degeneration: full overview → · Back & Disc Degeneration cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
طب تجديدي معتمد GMP في قلب الاتحاد الأوروبي — من 3,000 إلى 8,000 يورو، جزء بسيط من أسعار أمريكا أو ألمانيا. بروتوكولات مخصصة لمرضى من أكثر من 50 دولة.
مراجعة طبية مجانية